OBJECTIVE: To examine the effectiveness of an Internet intervention for depression with a randomized, controlled trial in a large sample of adults recruited from the United States. METHOD: The current study examines the effectiveness of Deprexis, an Internet treatment for depression that was provided with relatively minimal support. There were 376 treatment-seeking adults (mean age = 32 years; 74% female; 77% Caucasian, 7% Asian, 7% multiple races, 4% African American, and 11% Hispanic/Latino) with elevated depression (Quick Inventory of Depressive Symptoms-Self-Report [QIDS-SR] > = 10) who were randomized to receive an 8-week course of treatment immediately (n = 285) or after an 8-week delay (n = 91; i.e., waitlist control). RESULTS: Intention-to-treat analyses indicated that treatment was associated with greater reduction in self-reported symptoms of depression (effect size d = .80) and 12 times greater likelihood of experiencing at least 50% symptom improvement compared with waitlist control. Similar effects were observed for several secondary outcomes, such as interviewer-rated depression symptoms, well-being, and depression-related disability. Treatment effects for symptoms of social anxiety, panic, and traumatic intrusions were relatively small. CONCLUSION: Results suggest that Deprexis can produce symptomatic improvement among depressed adults recruited from the United States. Additional research is needed that examines whether improvements are maintained over time and who is particularly likely to respond to this form of treatment. (PsycINFO Database Record (c) 2017 APA, all rights reserved).
RCT Entities:
OBJECTIVE: To examine the effectiveness of an Internet intervention for depression with a randomized, controlled trial in a large sample of adults recruited from the United States. METHOD: The current study examines the effectiveness of Deprexis, an Internet treatment for depression that was provided with relatively minimal support. There were 376 treatment-seeking adults (mean age = 32 years; 74% female; 77% Caucasian, 7% Asian, 7% multiple races, 4% African American, and 11% Hispanic/Latino) with elevated depression (Quick Inventory of Depressive Symptoms-Self-Report [QIDS-SR] > = 10) who were randomized to receive an 8-week course of treatment immediately (n = 285) or after an 8-week delay (n = 91; i.e., waitlist control). RESULTS: Intention-to-treat analyses indicated that treatment was associated with greater reduction in self-reported symptoms of depression (effect size d = .80) and 12 times greater likelihood of experiencing at least 50% symptom improvement compared with waitlist control. Similar effects were observed for several secondary outcomes, such as interviewer-rated depression symptoms, well-being, and depression-related disability. Treatment effects for symptoms of social anxiety, panic, and traumatic intrusions were relatively small. CONCLUSION: Results suggest that Deprexis can produce symptomatic improvement among depressed adults recruited from the United States. Additional research is needed that examines whether improvements are maintained over time and who is particularly likely to respond to this form of treatment. (PsycINFO Database Record (c) 2017 APA, all rights reserved).
Authors: Franziska Holtdirk; Anja Mehnert; Mario Weiss; Johannes Mayer; Björn Meyer; Peter Bröde; Maren Claus; Carsten Watzl Journal: PLoS One Date: 2021-05-07 Impact factor: 3.240
Authors: Toshi A Furukawa; Aya Suganuma; Edoardo G Ostinelli; Gerhard Andersson; Christopher G Beevers; Jason Shumake; Thomas Berger; Florien Willemijn Boele; Claudia Buntrock; Per Carlbring; Isabella Choi; Helen Christensen; Andrew Mackinnon; Jennifer Dahne; Marcus J H Huibers; David D Ebert; Louise Farrer; Nicholas R Forand; Daniel R Strunk; Iony D Ezawa; Erik Forsell; Viktor Kaldo; Anna Geraedts; Simon Gilbody; Elizabeth Littlewood; Sally Brabyn; Heather D Hadjistavropoulos; Luke H Schneider; Robert Johansson; Robin Kenter; Marie Kivi; Cecilia Björkelund; Annet Kleiboer; Heleen Riper; Jan Philipp Klein; Johanna Schröder; Björn Meyer; Steffen Moritz; Lara Bücker; Ove Lintvedt; Peter Johansson; Johan Lundgren; Jeannette Milgrom; Alan W Gemmill; David C Mohr; Jesus Montero-Marin; Javier Garcia-Campayo; Stephanie Nobis; Anna-Carlotta Zarski; Kathleen O'Moore; Alishia D Williams; Jill M Newby; Sarah Perini; Rachel Phillips; Justine Schneider; Wendy Pots; Nicole E Pugh; Derek Richards; Isabelle M Rosso; Scott L Rauch; Lisa B Sheeber; Jessica Smith; Viola Spek; Victor J Pop; Burçin Ünlü; Kim M P van Bastelaar; Sanne van Luenen; Nadia Garnefski; Vivian Kraaij; Kristofer Vernmark; Lisanne Warmerdam; Annemieke van Straten; Pavle Zagorscak; Christine Knaevelsrud; Manuel Heinrich; Clara Miguel; Andrea Cipriani; Orestis Efthimiou; Eirini Karyotaki; Pim Cuijpers Journal: Lancet Psychiatry Date: 2021-05-03 Impact factor: 77.056
Authors: Björn Meyer; Mario Weiss; Martin Holtkamp; Stephan Arnold; Katja Brückner; Johanna Schröder; Franziska Scheibe; Yvonne Nestoriuc Journal: BMC Psychiatry Date: 2017-02-07 Impact factor: 3.630
Authors: Mark B Schure; Janet C Lindow; John H Greist; Paul A Nakonezny; Sandra J Bailey; William L Bryan; Matthew J Byerly Journal: J Med Internet Res Date: 2019-11-18 Impact factor: 5.428
Authors: Eirini Karyotaki; Orestis Efthimiou; Clara Miguel; Frederic Maas Genannt Bermpohl; Toshi A Furukawa; Pim Cuijpers; Heleen Riper; Vikram Patel; Adriana Mira; Alan W Gemmil; Albert S Yeung; Alfred Lange; Alishia D Williams; Andrew Mackinnon; Anna Geraedts; Annemieke van Straten; Björn Meyer; Cecilia Björkelund; Christine Knaevelsrud; Christopher G Beevers; Cristina Botella; Daniel R Strunk; David C Mohr; David D Ebert; David Kessler; Derek Richards; Elizabeth Littlewood; Erik Forsell; Fan Feng; Fang Wang; Gerhard Andersson; Heather Hadjistavropoulos; Heleen Christensen; Iony D Ezawa; Isabella Choi; Isabelle M Rosso; Jan Philipp Klein; Jason Shumake; Javier Garcia-Campayo; Jeannette Milgrom; Jessica Smith; Jesus Montero-Marin; Jill M Newby; Juana Bretón-López; Justine Schneider; Kristofer Vernmark; Lara Bücker; Lisa B Sheeber; Lisanne Warmerdam; Louise Farrer; Manuel Heinrich; Marcus J H Huibers; Marie Kivi; Martin Kraepelien; Nicholas R Forand; Nicky Pugh; Nils Lindefors; Ove Lintvedt; Pavle Zagorscak; Per Carlbring; Rachel Phillips; Robert Johansson; Ronald C Kessler; Sally Brabyn; Sarah Perini; Scott L Rauch; Simon Gilbody; Steffen Moritz; Thomas Berger; Victor Pop; Viktor Kaldo; Viola Spek; Yvonne Forsell Journal: JAMA Psychiatry Date: 2021-04-01 Impact factor: 21.596